BIO opposes US Senate biogenerics law

The Biotechnology Industry Organization has criticized the introduction of legislation in the US Senate to create a regulatory pathway for  generic versions of biotechnology drugs, which was proposed by  Senators Susan Collins (Republican, Maine), Charles Schumer (Democrat,  New York), Mel Martinez (Republican, Florida) and Sherrod Brown  (Democrat, Ohio).

Jim Greenwood, the BIO's president, said: "while well-intentioned, the  bill introduced today by Sens Schumer, Brown, Collins and Martinez  follows its companion bill in the House (HR 1427, the Promoting  Innovation and Access to Life-Saving Medicine Act) through the looking  glass to a world of biosimilars that would jeopardize patient safety and  undermine future medical breakthroughs."

Biologics "too complex" for quick generic approval by the FDA